论文部分内容阅读
[目的]探讨紫杉醇脂质体联合卡铂新辅助化疗(NACT)在Ⅰb2～Ⅱb期宫颈癌中的疗效。[方法]回顾性分析51例局部晚期宫颈癌行NACT后行根治性手术者(NACT组)与49例直接行手术治疗者(对照组)的临床资料,评价NACT的疗效及价值。[结果]NACT总有效率80.39%(41/51),化疗后51例患者均可行手术。化疗不良反应轻,术后并发症、术后切缘阳性率、淋巴结转移率及脉管瘤栓阳性率均低于对照组(P<0.05)。[结论]紫杉醇脂质体联合卡铂在Ⅰb～Ⅱb期宫颈癌行新辅助化疗后可缩小肿瘤病灶,为手术创造条件。
[Objective] To investigate the efficacy of paclitaxel liposome combined with carboplatin neoadjuvant chemotherapy (NACT) in stage Ⅰb2 ~ Ⅱb cervical cancer. [Methods] The clinical data of 51 patients with locally advanced cervical cancer who underwent radical surgery (NACT group) and 49 patients who underwent direct surgical operation (control group) were retrospectively analyzed to evaluate the efficacy and value of NACT. [Results] The total effective rate of NACT was 80.39% (41/51). All 51 patients underwent chemotherapy after surgery. The adverse reactions of chemotherapy were mild, postoperative complications, positive margins after surgery, lymph node metastasis rate and positive rate of vascular tumor thrombus were lower than those in control group (P <0.05). [Conclusion] Paclitaxel liposomes combined with carboplatin can reduce the tumor focus after neoadjuvant chemotherapy in stage Ⅰb ~ Ⅱb cervical cancer and create conditions for operation.